NxtGen is betting that sovereignty, vertical integration and India-specific AI will matter more than sheer hardware volume ...
Sophie Koonin discusses the realities of large-scale technical migrations, using Monzo’s shift to TypeScript as a roadmap. She explains how to handle "bends in the road," from documentation and ...
From the browser to the back end, the ‘boring’ choice is exciting again. We look at three trends converging to bring SQL back ...
JPLoft enhances its web development services, empowering businesses with advanced technologies for faster digital ...
Fabricate: AI app builder generating React/TypeScript code with databases, Stripe payments, authentication, and Cloudflare edge deployment - no coding needed. Users fully own all source code. The ...
Fabricate: AI app builder generating React/TypeScript code with databases, Stripe payments, authentication, and Cloudflare edge deployment - no coding needed. Users fully own all source code.
The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
A sophisticated, full-stack web application for Café Fausse, an elegant fine-dining restaurant. This project features a React frontend with responsive design, Flask REST API backend, and PostgreSQL ...
Washington — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. A sign marks an entrance to a Moderna building in ...
Moderna says FDA refuses its application for new mRNA flu vaccine The FDA cited concerns about Moderna's use of a 40,000-person clinical trial that showed improved effectiveness in adults 50 and older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results